The clinical performance of three rapidly performed tests--tap test, TDx Fetal Lung Maturity and amniotic fluid absorbance at 650 nm--in predicting fetal lung maturity were evaluated in 300 samples of clear amniotic fluid. In all cases, delivery occurred within three days of sample collection. Of the 300 newborns, 44 developed respiratory distress syndrome. For the tap test, the sensitivity (95.4%), specificity (82.8%), and predictive value for maturity (99.7%) and immaturity (48.9%) were comparable to those of the TDx fetal lung maturity test: sensitivity of 100%, specificity of 88.3%, and predictive value for maturity of 100% and immaturity of 53.1%. The specificity (68.4%) and predictive value for immaturity (34.7%) of amniotic fluid absorbance at 650 nm were significantly lower than for the TDx and tap tests, whereas no significant difference was found for sensitivity and prediction of maturity between amniotic fluid absorbance at 650 nm and the TDx and tap tests. Both the tap and the TDx tests appear to be useful in antenatal assessment of fetal lung maturity in terms of reliability, rapidity and uniformity.

Cancers2区 · 医学

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma

2区 · 医学

ArticleOA

作者: Sala, Gianluca ; Iacobelli, Valentina ; Di Vittorio, Giulia ; Capone, Emily ; Ponzoni, Mirco ; Ponziani, Sara ; Iezzi, Manuela ; Rossi, Cosmo ; Panella, Valeria ; Bibbò, Sandra ; De Laurenzi, Vincenzo ; Giansanti, Francesco ; Piccolo, Enza ; Iacobelli, Stefano ; Lamolinara, Alessia ; Lattanzio, Rossano ; Sala, Arturo ; Gentile, Roberta ; D’Agostino, Daniela ; Ippoliti, Rodolfo ; Sallese, Michele ; Pastorino, Fabio

Neuroblastoma is the most common extra-cranial solid tumor in infants and children, which accounts for approximately 15% of all cancer-related deaths in the pediatric population. New therapeutic modalities are urgently needed. Antibody-Drug Conjugates (ADC)s-based therapy has been proposed as potential strategy to treat this pediatric malignancy. LGALS3BP is a highly glycosylated protein involved in tumor growth and progression. Studies have shown that LGALS3BP is enriched in extracellular vesicles (EV)s derived by most neuroblastoma cells, where it plays a critical role in preparing a favorable tumor microenvironment (TME) through direct cross talk between cancer and stroma cells. Here, we describe the development of a non-internalizing LGALS3BP ADC, named 1959-sss/DM3, which selectively targets LGALS3BP expressing neuroblastoma. 1959-sss/DM3 mediated potent therapeutic activity in different types of neuroblastoma models. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative. These results offer preclinical proof-of-concept for an ADC targeting exosomal LGALS3BP approach for neuroblastomas.

100 项与 1959-sss-DM3 相关的药物交易

登录后查看更多信息